We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$661M
AUM Growth
+$34.1M
Cap. Flow
-$6.85M
Cap. Flow %
-1.04%
Top 10 Hldgs %
25.72%
Holding
101
New
10
Increased
24
Reduced
44
Closed
5

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$12.3M
2
ABMD
Abiomed Inc
ABMD
+$12.2M
3
WBA
Walgreens Boots Alliance
WBA
+$11.2M
4
CVS icon
CVS Health
CVS
+$8.13M
5
BHC icon
Bausch Health
BHC
+$7.75M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.33M
2
ALKS icon
Alkermes
ALKS
+$6.79M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.92M
4
HCA icon
HCA Healthcare
HCA
+$5.86M
5
EW icon
Edwards Lifesciences
EW
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRGO icon
1
Perrigo
PRGO
$1.4B
$21M 3.17%
145,000
+80,000
+123% +$12.3M
ABMD
2
DELISTED
Abiomed Inc
ABMD
$19.9M 3%
220,000
+144,000
+189% +$12.2M
MDT icon
3
Medtronic
MDT
$109B
$19.2M 2.9%
249,000
-16,000
-6% -$1.2M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$19.1M 2.88%
100,000
-15,000
-13% -$2.62M
CVS icon
5
CVS Health
CVS
$133B
$17.6M 2.66%
180,000
+83,000
+86% +$8.13M
AGN
6
DELISTED
Allergan plc
AGN
$17.2M 2.6%
55,000
+9,000
+20% +$2.68M
ABBV icon
7
AbbVie
ABBV
$443B
$14.6M 2.2%
246,000
+36,000
+17% +$2.07M
UNH icon
8
UnitedHealth
UNH
$376B
$14.2M 2.15%
121,000
-26,000
-18% -$3.04M
PFE icon
9
Pfizer
PFE
$143B
$14.1M 2.14%
461,652
+17,918
+4% +$564K
AMGN icon
10
Amgen
AMGN
$208B
$13.3M 2.01%
82,000
-53,000
-39% -$8.33M
CI icon
11
Cigna
CI
$73.7B
$12.7M 1.92%
87,000
-18,900
-18% -$2.6M
BMY icon
12
Bristol-Myers Squibb
BMY
$133B
$12.6M 1.9%
183,000
-9,000
-5% -$595K
GILD icon
13
Gilead Sciences
GILD
$162B
$12.5M 1.9%
124,000
+9,000
+8% +$936K
ALKS icon
14
Alkermes
ALKS
$8.22B
$12.5M 1.9%
158,000
-97,000
-38% -$6.79M
CELG
15
DELISTED
Celgene Corp
CELG
$12.5M 1.88%
104,000
-32,000
-24% -$3.7M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.6B
$12.4M 1.87%
118,000
+32,000
+37% +$3.34M
LLY icon
17
Eli Lilly
LLY
$1.02T
$12.3M 1.86%
146,000
-39,000
-21% -$3.24M
ELV icon
18
Elevance Health
ELV
$81.5B
$12.3M 1.86%
88,000
-19,000
-18% -$2.62M
INCY icon
19
Incyte
INCY
$24.2B
$11.9M 1.8%
110,000
+1,000
+0.9% +$112K
MCK icon
20
McKesson
MCK
$100B
$11.6M 1.76%
59,000
-18,000
-23% -$3.4M
REGN icon
21
Regeneron Pharmaceuticals
REGN
$78.5B
$11.4M 1.72%
21,000
+4,500
+27% +$2.44M
AET
22
DELISTED
Aetna Inc
AET
$11.2M 1.7%
104,000
-34,000
-25% -$3.68M
WBA
23
DELISTED
Walgreens Boots Alliance
WBA
$11.2M 1.7%
+132,000
New +$11.2M
ZBH icon
24
Zimmer Biomet
ZBH
$18.2B
$11M 1.66%
110,210
+38,110
+53% +$3.73M
HUM icon
25
Humana
HUM
$43.7B
$10.9M 1.65%
61,000
-19,000
-24% -$3.33M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rhenman & Partners Asset Management held 101 positions worth $661M, up 5.4% from $627M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q4 2015 filing shows 10 new, 24 increased, 44 reduced and 5 closed positions. Its largest new stake was Walgreens Boots Alliance: 132,000 shares worth $11.2M. The largest sale was Amgen, an estimated $8.33M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q4 2015 buy was Walgreens Boots Alliance: 132,000 shares worth $11.2M.
  • Rhenman & Partners Asset Management added most to Perrigo in Q4 2015, an estimated $12.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2015 reduction was Amgen, cutting an estimated $8.33M.
  • Rhenman & Partners Asset Management fully exited Merck in Q4 2015, selling an estimated $4.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $661M portfolio in Q4 2015.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q4 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $661M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.